Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study

• DOI: 10.2340/actadv.v102.1995
• Publication Date: 2022-05-23T12:54:35Z
• Authors: Florian Herms; Barouyr Baroudjian; Julie Delyon; Pauline Laly; Pauline Tetu; Celeste Lebbe; Nicole Basset-Seguin
• Keywords: Tolerability; Discontinuation; Dysgeusia

Sonidegib, a hedgehog pathway inhibitor, is indicated for treatment of locally advanced basal cell carcinoma, based on the results BOLT study. However, to date, no real-world study sonidegib has been reported. An observational, retrospective, single-centre (PaSoS study) was conducted. The primary objective evaluate efficacy carcinoma in setting. Secondary objectives included modalities use, tolerability, tumour evolution, and management after discontinuation. A total 21 patients treated with were from March 2018 January 2021. median follow-up 18.7 months exposure 7.0 months. Objective response (OR) rate 81.0% (n = 17) including 6 (29%) complete (CR). Disease control 100%. First rapid, time 2.3 Nine (43%) underwent surgery discontinuation, relapse observed. All experienced at least 1 adverse event (AE). Muscle spasms most frequent AE 14; 67%), followed by dysgeusia 8; 38%) alopecia 12; 57%). safety profile this first-to-date real-life trial are consistent prior results. Overall, evidence corroborated tolerability as first-line carcinoma.